P-glycoprotein acts as a protective barrier by transporting certain medications and toxins out of cells, particularly within the brain. Dogs with the MDR1 mutation have impaired transporter function, allowing some drugs to accumulate to dangerous levels. As a result, medications that are normally safe for most dogs may cause severe neurological and systemic side effects in affected animals.
Clinical signs associated with MDR1-related drug sensitivity typically occur only after exposure to certain medications. Depending on the drug and dosage involved, affected dogs may experience symptoms such as excessive drooling, vomiting, diarrhea, lethargy, weakness, loss of coordination, tremors, disorientation, vision problems, seizures, respiratory distress, coma, or even death in severe cases. Because dogs carrying the mutation often appear healthy until exposed to a problematic medication, genetic testing is the most effective way to identify those at risk.
The MDR1 DNA Health Test is designed to detect the specific mutation responsible for this inherited drug sensitivity. Testing is simple and non-invasive, requiring either a cheek swab or blood sample. The collected sample is analyzed in a specialized laboratory to determine the dog's genetic status. Since DNA remains unchanged throughout life, testing can be performed at any age, including in puppies before they receive medications that may pose a risk.
Results are typically reported in one of three categories:
- Clear (Normal): The dog has two normal copies of the MDR1 gene and is unlikely to have increased sensitivity to MDR1-associated medications.
- Carrier: The dog has one normal copy and one mutated copy of the gene. Carriers may exhibit mild drug sensitivity and can pass the mutation to their offspring.
- Affected: The dog has two copies of the mutated gene and is at significantly increased risk of severe adverse reactions to certain medications.
The MDR1 mutation is particularly common in several herding and working breeds, although it can also occur in mixed-breed dogs and other purebred populations. Genetic testing provides valuable information for veterinarians, allowing them to select appropriate medications, adjust dosages when necessary, and avoid drugs that may trigger toxic reactions.
For breeders, MDR1 testing is an important component of responsible breeding programs. By identifying clear, carrier, and affected dogs, breeders can make informed mating decisions that help reduce the prevalence of the mutation while maintaining healthy genetic diversity within the breed.
For dog owners, knowing a pet’s MDR1 status can help prevent avoidable medical emergencies and support safer veterinary care throughout the dog's life. Early identification allows veterinarians to tailor treatment plans and select medications that minimize risk.
The Multi Drug Resistance (MDR1) Health Test is a reliable genetic screening tool that helps identify dogs at risk for medication sensitivity. Through early detection, informed healthcare decisions, and responsible breeding practices, the impact of MDR1-related drug reactions can be significantly reduced, contributing to healthier and safer lives for dogs.
